Lung Cancer News and Research

Latest Lung Cancer News and Research

University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that the University Hospital Bonn in Germany will initiate a clinical confirmatory study to assess VolitionRx’s proprietary Nucleosomics platform technology for the diagnosis of lung cancer through a blood test in individuals.

18 Dec 2014

Postop chemotherapy supported for stage III NSCLC

Study findings challenge the belief that preoperative chemotherapy is superior to postoperative chemotherapy for patients with clinical stage III non-small-cell lung cancer.

17 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Lung cancer in women: an interview with Harold Wimmer and Chuck Brynelsen

We at the American Lung Association know that lung cancer is the number one cancer killer among women, however, there is a startling lack of information available to the public regarding lung cancer.

16 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report.

15 Dec 2014

New holistic approach to cancer treatment

The University of Texas MD Anderson Cancer Center and UnitedHealthcare have launched a pilot to explore a new cancer care payment model for head and neck cancers that focuses on quality patient care and outcomes. The collaboration is among the first using bundled payments in a large, comprehensive cancer center.

15 Dec 2014

Olympus receives FDA clearance for Narrow Band Imaging

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today FDA 510(k) clearance of Narrow Band Imaging (NBI) as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor boundaries in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients.

From Evident Corporation - Life Sciences 15 Dec 2014

Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Back pain is exceptionally common. In fact, to not experience back pain at some point of your life would be thoroughly abnormal. Experiencing back pain is like becoming tired or becoming sad; we don’t necessarily like it, but it’s perfectly common.

14 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

12 Dec 2014

Metastatic lung cancer outcomes independent of KRAS mutation subtypes

Overall survival in patients with metastatic lung cancer does not correlate with Kirsten rat sarcoma viral oncogene homologue mutation subtypes, US researchers report.

12 Dec 2014

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations.

11 Dec 2014

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

Research suggests that treatment with cisplatin plus S-1 together with thoracic radiotherapy is relatively efficacious and tolerable in patients with locally advanced non-small-cell lung cancer.

11 Dec 2014

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

With cancer rates rising worldwide, and Cancer Research UK predicting that the lifetime risk of cancer will reach 50% by 2027, the need for early diagnosis is overwhelming. Now, a British research group has published details of a simple empirical test to detect any early-stage cancer, relying on Andor's Komet software to automatically score the modified 3D 'Comet' assay results.

From Andor Technology Ltd. 11 Dec 2014

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

A multicentre, phase II study of carboplatin and paclitaxel in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy.

10 Dec 2014

Myriad Genetics highlights three new studies at SABCS 2014

Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.

10 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

Cigarette smoking continues to cause nearly three in ten cancer deaths in the U.S.

A new American Cancer Society study finds that despite significant drops in smoking rates, cigarettes continue to cause about three in ten cancer deaths in the United States. The study, appearing in the Annals of Epidemiology, concludes that efforts to reduce smoking prevalence as rapidly as possible should be a top priority for the U.S. public health efforts to prevent cancer deaths.

10 Dec 2014

Advances in fight against TB, sudden cardiac death

Research projects into two of the biggest killers in worldwide health, tuberculosis and sudden cardiac death, will be the subjects of the University of Leicester Graduate School Doctoral Inaugural Lectures, delivered by two of the winners of this year's PhD prizes in the College of Medicine, Biological Sciences and Engineering.

10 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

Agent THZ1 shrinks human-like small cell lung tumors in mice

Small cell lung cancer - a disease for which no new drugs have been approved for many years - has shown itself vulnerable to an agent that disables part of tumor cells' basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

9 Dec 2014